Company: BIVIW
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001520138-25-000144
Chunk: 83

Company: BIOVIE INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 83
---
ations of approximately $127,000.

 24 

The decrease in clinical studies of approximately $7.6 million represented
the net decrease in clinical trial studies expense of approximately $11.6 million due the completion of the clinical trials in the prior
fiscal year offset by the planning and development of the two new clinical studies, Sunrise PD Phase 2 and Long Covid Program, totaling
approximately $4.0 million. The table below summarizes the expense amounts for the nine months ended March 31, 2025 and 2024 by study:

    Nine Months Ended  
    Nine Months Ended  
    Increase 

    March 31, 2025  
    March 31, 2024  
    (Decrease) 

    Current Studies 

    Sunrise PD Phase 2 
    $2,640,572  
    $20,000  
    $2,620,572 
  
    Liver Program Phase 3 
     135,888  
     39,880  
     96,008 
  
    Long Covid Program, net of $2.8 million reimbursement 
     1,313,294  
     -  
     1,313,294 
  
    Investigator-Initiated studies 
     24,763  
     9,199  
     15,564 

    $4,114,517  
    $69,079  
    $4,045,438 

    Completed Studies 

    Ascites BIV201 Phase 2b 
    $(63,773) 
    $595,014  
    $(658,787)
  
    AD mild to moderate pivotal Phase 3 
     18,034  
     9,051,902  
     (9,033,868)
  
    PD Phase 2 
     -  
     601,080  
     (601,080)
  
     Investigator-Initiated studies 
     -  
     88,986  
     (88,986)
  
    Other studies in development/canceled 
     18,253  
     1,275,422  
     (1,257,169)

    $(27,486) 
    $11,612,404  
    $(11,639,890)

 25 

Selling, General and Administrative Expenses

Selling,